We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pediatrix Medical's Q3 Test: Can Lower Expenses Drive Earnings?
Read MoreHide Full Article
Key Takeaways
Pediatrix Medical will release third-quarter 2025 results on Nov. 3, before the opening bell.
Q3 EPS estimate of 46 cents implies 4.6% growth, but revenue estimate of $484.1M signals a 5.3% drop.
Lower operating expenses, including salaries and G&A, may help boost Pediatrix Medical's bottom line.
Pediatrix Medical Group, Inc. (MD - Free Report) is set to report its third-quarter 2025 results on Nov. 3, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 46 cents per share and $484.1 million, respectively.
The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year-over-year increase of 4.6%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decrease of 5.3%.
Image Source: Zacks Investment Research
For 2025, the Zacks Consensus Estimate for Pediatrix Medical’s revenues is pegged at $1.89 billion, implying a decline of 6% year over year. Yet, the consensus mark for the current year EPS is pegged at $1.78, implying growth of 17.9% on a year-over-year basis.
Pediatrix Medical beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 28.7%, as you can see below.
Pediatrix Medical Group, Inc. Price and EPS Surprise
However, our proven model does not conclusively predict an earnings beat for MD this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
MDhas an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Let’s see how things have shaped up before the third-quarter earnings announcement.
Q3 Factors to Note for Pediatrix Medical
Both the Zacks Consensus Estimate and our model estimate for third-quarter net patient service revenue indicate a 7.4% year-over-year decline. Moreover, both the consensus mark and our model estimate for hospital contract administrative fees suggest a 5.7% decline from a year ago. These are likely to have affected the company’s top line in the third quarter.
The Zacks Consensus Estimate for same-facility revenue growth is pegged at 3.35% for the third quarter, as the same-facility patient volume growth is pegged at 1.3% and same-facility net reimbursement growth is pegged at 2.05%. The consensus mark for same-facility NICU patient days growth is pegged at 4%.
Our model estimate for total operating expenses indicates a nearly 11% year-over-year decline. Lower practice salaries & benefits, supplies & other expenses, and G&A costs are likely to have aided its bottom line.
Our model estimate for third-quarter interest expense is pegged at more than $9 million, indicating a continued year-over-year decline in the metric. We expect Pediatrix Medical’s third-quarter operating cash flow to be nearly $121 million, a significant jump from the year-ago period.
How Did Other Stocks Perform?
Here are some stocks in the broader Medical space that have already reported earnings for this quarter: HCA Healthcare, Inc. (HCA - Free Report) , Universal Health Services, Inc. (UHS - Free Report) and Community Health Systems, Inc. (CYH - Free Report) .
HCA Healthcare reported third-quarter 2025 adjusted EPS of $6.96, which surpassed the Zacks Consensus Estimate by 23.2%. The bottom line improved 42% year over year. The results were aided by growing patient volumes, higher same-facility revenue per equivalent admission, and an increased number of surgeries. However, the upside was partly offset by HCA Healthcare’s escalating costs.
Universal Health reported third-quarter 2025 adjusted EPS of $5.69, which outpaced the Zacks Consensus Estimate by 22.1%. The bottom line soared 53.4% year over year. The results benefited from robust performance in both Acute Care and Behavioral Health segments. Increased adjusted admissions and improved patient days boosted segmental revenues. However, the upside was partly offset by Universal Health’s elevated operating costs.
Community Health posted third-quarter 2025 adjusted earnings of $1.27 per share, which beat the Zacks Consensus Estimate of a loss of 32 cents. The bottom line improved from the prior-year loss of 30 cents. The quarterly results benefited from declining expenses, favorable changes in payor mix and increased same-store admissions. However, a decrease in Community Health’s patient days, occupancy rate and adjusted admissions partially offset the positives.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pediatrix Medical's Q3 Test: Can Lower Expenses Drive Earnings?
Key Takeaways
Pediatrix Medical Group, Inc. (MD - Free Report) is set to report its third-quarter 2025 results on Nov. 3, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 46 cents per share and $484.1 million, respectively.
The earnings estimate for the to-be-reported quarter has remained stable over the past 60 days. The bottom-line projection indicates a year-over-year increase of 4.6%. However, the Zacks Consensus Estimate for quarterly revenues suggests a year-over-year decrease of 5.3%.
Image Source: Zacks Investment Research
For 2025, the Zacks Consensus Estimate for Pediatrix Medical’s revenues is pegged at $1.89 billion, implying a decline of 6% year over year. Yet, the consensus mark for the current year EPS is pegged at $1.78, implying growth of 17.9% on a year-over-year basis.
Pediatrix Medical beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 28.7%, as you can see below.
Pediatrix Medical Group, Inc. Price and EPS Surprise
Pediatrix Medical Group, Inc. price-eps-surprise | Pediatrix Medical Group, Inc. Quote
Pediatrix Medical’s Q3 Earnings Whispers
However, our proven model does not conclusively predict an earnings beat for MD this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
MDhas an Earnings ESP of 0.00% and a Zacks Rank #3. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Let’s see how things have shaped up before the third-quarter earnings announcement.
Q3 Factors to Note for Pediatrix Medical
Both the Zacks Consensus Estimate and our model estimate for third-quarter net patient service revenue indicate a 7.4% year-over-year decline. Moreover, both the consensus mark and our model estimate for hospital contract administrative fees suggest a 5.7% decline from a year ago. These are likely to have affected the company’s top line in the third quarter.
The Zacks Consensus Estimate for same-facility revenue growth is pegged at 3.35% for the third quarter, as the same-facility patient volume growth is pegged at 1.3% and same-facility net reimbursement growth is pegged at 2.05%. The consensus mark for same-facility NICU patient days growth is pegged at 4%.
Our model estimate for total operating expenses indicates a nearly 11% year-over-year decline. Lower practice salaries & benefits, supplies & other expenses, and G&A costs are likely to have aided its bottom line.
Our model estimate for third-quarter interest expense is pegged at more than $9 million, indicating a continued year-over-year decline in the metric. We expect Pediatrix Medical’s third-quarter operating cash flow to be nearly $121 million, a significant jump from the year-ago period.
How Did Other Stocks Perform?
Here are some stocks in the broader Medical space that have already reported earnings for this quarter: HCA Healthcare, Inc. (HCA - Free Report) , Universal Health Services, Inc. (UHS - Free Report) and Community Health Systems, Inc. (CYH - Free Report) .
HCA Healthcare reported third-quarter 2025 adjusted EPS of $6.96, which surpassed the Zacks Consensus Estimate by 23.2%. The bottom line improved 42% year over year. The results were aided by growing patient volumes, higher same-facility revenue per equivalent admission, and an increased number of surgeries. However, the upside was partly offset by HCA Healthcare’s escalating costs.
Universal Health reported third-quarter 2025 adjusted EPS of $5.69, which outpaced the Zacks Consensus Estimate by 22.1%. The bottom line soared 53.4% year over year. The results benefited from robust performance in both Acute Care and Behavioral Health segments. Increased adjusted admissions and improved patient days boosted segmental revenues. However, the upside was partly offset by Universal Health’s elevated operating costs.
Community Health posted third-quarter 2025 adjusted earnings of $1.27 per share, which beat the Zacks Consensus Estimate of a loss of 32 cents. The bottom line improved from the prior-year loss of 30 cents. The quarterly results benefited from declining expenses, favorable changes in payor mix and increased same-store admissions. However, a decrease in Community Health’s patient days, occupancy rate and adjusted admissions partially offset the positives.